Read our latest updates & insights

On 25 June 2024, Evotec announced that its subsidiary, Just – Evotec Biologics, Inc., has been selected by the U.S. Department of Defense to develop an accelerated monoclonal antibody development and manufacturing solution as part of the department’s Manufacturing Optimizat...

On 24 June 2024, Biogen announced its IV tocilizumab, TOFIDENCE™, biosimilar to Roche’s ROACTEMRA®, has been approved by EC.  Tofidence is authorised by the EC for treating moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic...

On 24 June 2024, Teva Pharmaceuticals announced the US launch of its authorised generic liraglutide injection (1.8 mg) for type 2 diabetes.  Originator Novo Nordisk supplies liraglutide as Victoza®, and Teva’s authorised generic Victoza is the first generic GLP-1 treatment ...

On 24 June 2024, Biocon Biologics announced that it received approval from the European Medicines Agency to manufacture biosimilar bevacizumab from its  multi-product mAbs facility at Bengaluru. 

Biocon received EC authorisation for its Abevmy® (biosimilar bevacizuma...

On 21 June 2025, Argenx announced that the FDA approved a new indication of its VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for chronic inflammatory demyelinating polyneuropathy (CIDP).  

VYVGART Hytrulo is approved for CIDP, administered as a subcuta...

Results of phase 3 pertuzumab studies comparing Qilu’s QL1209 with Roche’s Perjeta® with trastuzumab and docetaxel were published in the British Journal of Cancer on 21 June 2024.  

The studies demonstrated that QL1209 is equivalent to Perjeta® in safety and efficacy ...

On 14 and 21 June, respectively, the United States District Court for the Northern District of West Virginia granted Regeneron’s motions for preliminary injunctions against Samsung Bioepis and Formcyon (unpublished to date), preventing them from launching their US biosimila...

On 20 June 2024, Amgen’s WezenlaTM, biosimilar to Janssen’s Stelara® (ustekinumab) received marketing authorisation in Europe.  This followed a positive CHMP recommendation in April 2024.

Wezlana™ was approved in the US in October 2023, was launched in Canada in Marc...

On 20 June 2024, Korea Biomedical Review reported that Celltrion has successfully applied to be the exclusive supplier of Remsima® (biosimilar to Janssen’s Remicade® (infliximab)), Herzuma® (biosimilar to Roche’s Herceptin® (trastuzumab)) and Vegzelma® (biosimilar to Genent...